Navigation Links
Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
Date:10/1/2007

- Former Research Team Director and Key Strategy Architect to Build on

Foundation's Momentum In Pursuing Systemic Changes to Advance in

Parkinson's Disease Treatments -

NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced that Katie Hood, Deputy Chief Executive Officer and former Research Director, has been appointed Interim Chief Executive Officer. Ms. Hood, who joined the Foundation in September 2002, has played critical roles in shaping its strategy of intervening aggressively to close critical gaps in the process of moving potential treatments from the laboratory to Parkinson's patients, as well as in building a team of in-house research experts needed to implement that strategy.

Ms. Hood replaces CEO Sarah Orsay, who is leaving MJFF in order to devote more time to her three children.

MJFF Founder Michael J. Fox said, "The Michael J. Fox Foundation has grown enormously in our sophistication and in our capability to work with everyone from academic researchers to industry in plugging the many gaps in the process that keep promising science from advancing to effective, life-changing treatments for Parkinson's. Katie Hood has played a big part in that evolution, and we're confident that with her at the helm, we will not only maintain our momentum but will continue to build our reputation for not just throwing money at the problem, but truly taking a leadership role in helping identify and cultivate research breakthroughs."

Ms. Hood stated, "After five years working with management and staff at all levels of MJFF, as well as our scientific advisors, grantees, industry partners and donors, I am looking forward to working with Michael, our Board and our entire team to further advance the mission and strategy of a foundation that is increasingly setting the standard for effectiveness and best business practices."

As Interim Chief Executive Officer, Ms. Hood will provide day-to-day management and oversight of all Foundation activities and will specifically oversee fundraising, the Foundation's research team and communications, administration and financial management. Ms. Hood will report to the Board of Directors. Debi Brooks will continue to serve as co-founder with a focus on principal-gifts fundraising and outreach to key external audiences, reporting to the Board of Directors.

The Foundation stated that Ms. Hood will be a candidate to assume the CEO position on a permanent basis.

Prior to joining the Foundation, Ms. Hood was employed as a consultant at Bain & Company in New York City, doing work in the consumer products, financial services, and nonprofit sectors. She has also served as an analyst in the Credit Department of Goldman, Sachs & Co., and as a program coordinator with Duke University's Hart Leadership Program. Ms. Hood graduated from Harvard Business School, and holds a BA in Public Policy Studies from Duke University in Durham, North Carolina.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded more than $95 million in research to date, either directly or through partnerships. For more information please visit the Foundation's Web site at http://www.michaeljfox.org.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Katee Holmes Vs Katie Holmes Case of Losing Virginity
2. Katie Holmes in most Influential Celebs List
3. Wood Appointed As the First Chair of SAADAT
4. Yoga Guru appointed Bihars brand ambassador
5. Disappointed Students Plan To Intensify Agitation Nationwide
6. City Surgeon Appointed Adviser To Armed Forces
7. Indian-American Appointed for US Hospital Top Post
8. Retiring Government Doctors to Be Reappointed to Overcome Paucity of Specialists
9. Bruce Vladeck Will Hold Fort (interim) of UMDNJ
10. Interim WHO Chief Confirms No radical changes in WHO
11. Interim OPD saves the day for patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: